Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Transfer of metformin into human breast milk and the plasma of breastfeeding children - A low intervention trial with biobanking of breast m… Ended

2022-501693-19-00 type 2 diabetes mellitus and gestational diabetes melli 6 2024-03-06
Transfer of prednisolone into human breast milk and plasma of breastfeeding children Ended

2023-508913-18-00 Reumatoid Arthritis, SLE, myositis, psoriatric arthriti 6 2024-03-05
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma Ended

2023-504304-29-00 Moderate to Severe Asthma 3 2024-03-01
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by t… Ended

2023-508030-33-00 Healthy volunteers 8 2024-03-01
A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus Ended

2023-506499-29-00 Systemic Lupus Erythematosus 3 2024-02-28
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub… Ended

2023-508013-16-00 Birch pollen induced allergic rhinitis or rhinoconjunct 5 2024-02-26
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses Ended

2023-507882-24-00 Inflammatory Gastrointestinal Disease 1 2024-02-20
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-502461-23-00 Prurigo Nodularis 5 2024-02-15
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Ended

2023-505127-31-00 Rheumatoid Arthritis 3 2024-02-08
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Cer… Ended

2023-504045-31-00 Rheumatoid Arthritis 4 2024-02-08
A Study to Learn How Different Manufactured Products of the Study Medicine Called Ritlecitinib are Taken up Into the Blood in Healthy Adults… Ended

2023-505603-23-00 ulcerative colitis, Crohn’s Disease, alopecia areata, r 3 2024-01-29
This study will use a new investigation study drug called OMS906 in peoplewith C3 Glomerulopathy (C3G) or Idiopathic Immune Complex-Mediated… Ended

2023-508669-33-00 C3 Glomerulopathy and Idiopathic Immune Complex-Mediate 4 2024-01-29
An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharma… Ended

2023-507134-25-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 3 2024-01-29
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic fun… Ended

2023-508519-22-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 3 2024-01-26
A phase IV, open, non-randomised, low-intervention clinical trial to evaluate the subjective user experience of Zeqmelit™ 6 mg mouth dissolv… Ended

2023-504975-25-00 Acute allergic reaction 11 2024-01-26
A study to evaluate efficacy and safety of SAR441566 in adults with plaque psoriasis Ended

2023-503911-14-00 Psoriasis 4 2024-01-25
A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) Ended

2023-503502-37-00 Non segmental vitiligo 4 2024-01-24
A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered to… Ended

2023-506580-34-00 Healthy Volunteers 3 2024-01-04
An open-label, cross-over, multi-site, prospective, phase IIb study of effects on circadian rhythms and quality of life of modifieddual-rele… Ended

2023-503584-42-00 Addison’s Disease 4 2023-12-22
A Phase 2 Multicenter Study to Evaluate PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations Ended

2023-503343-33-00 Active Cutaneous Lupus Erythematosus (CLE) or Systemic 4 2023-12-21
A Sub Study to Learn About the Study Medication Called Etrasimod Tablets in a Hybrid Decentralized Clinical Trial Setting Ended

2023-508119-22-00 immune-mediated inflammatory disorders, including ulcer 3 2023-12-18
A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2i Ended

2023-503828-13-00 Nephrology 4 2023-12-12
A study to investigate the pharmacokinetics of remibrutinib in CSF in healthy participants. Ended

2023-506760-13-00 Healthy 3 2023-12-11